Currently, CAG Cagrilintide provides constrained access across EU nations. Although research programs showed positive outcomes for patients living with this condition, general accessibility remains a hurdle. Authorization processes in individual EU member states are necessary to facilitate {widespread implementation and patient well-being. Further